MedTrace Logo

Novel Compositions for Treating or Preventing Dermal Disorders

NCT03103893 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-09-22

No results posted yet for this study

Summary

This trial examines the impact of a topical formulation of rapamycin on dermal thickness and senescence.

Conditions

  • Dermal Atrophy

Interventions

DRUG

Rapamycin

topical formulation

Sponsors & Collaborators

  • Drexel University

    lead OTHER

Principal Investigators

  • Christian Sell, PhD · Faculty member

  • Christina Chung, MD · Drexel University College of Medicine

  • Ibiyonu Lawrence, MD · Drexel University College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-25
Primary Completion
2017-11-30
Completion
2017-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03103893 on ClinicalTrials.gov